Cargando…

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies

Broadly neutralizing antibodies (bNAbs) that target the membrane-proximal external region (MPER) of HIV gp41 envelope, such as 4E10, VRC42.01 and PGZL1, can neutralize >80% of viruses. These three MPER-directed monoclonal antibodies share germline antibody genes (IGHV1-69 and IGKV3-20) and form a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheepers, Cathrine, Kgagudi, Prudence, Mzindle, Nonkululeko, Gray, Elin S., Moyo-Gwete, Thandeka, Lambson, Bronwen E., Oosthuysen, Brent, Mabvakure, Batsirai, Garrett, Nigel J., Abdool Karim, Salim S., Morris, Lynn, Moore, Penny L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477419/ https://www.ncbi.nlm.nih.gov/pubmed/36054228 http://dx.doi.org/10.1371/journal.ppat.1010450

Ejemplares similares

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022)

Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape
por: Scheepers, Cathrine, et al.
Publicado: (2020)

Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies
por: Mabvakure, Batsirai M., et al.
Publicado: (2019)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
por: Kitchin, Dale, et al.
Publicado: (2022)

Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12
por: Tumba, NL, et al.
Publicado: (2012)

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
por: Richardson, Simone I., et al.
Publicado: (2019)

A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies
por: Mabvakure, B., et al.
Publicado: (2017)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth
por: Sheward, Daniel J., et al.
Publicado: (2018)

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth
por: Chukwuma, Valentine U., et al.
Publicado: (2018)

Refined identification of neutralization-resistant CRF02_AG viruses and their sensitivity to anti-MPER neutralizing antibodies
por: Jacob, RA, et al.
Publicado: (2012)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection
por: Moore, Penny L., et al.
Publicado: (2009)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
por: van den Berg, Fiona T., et al.
Publicado: (2019)

Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
por: Krebs, Shelly J., et al.
Publicado: (2014)

MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
por: Ruprecht, Claudia R., et al.
Publicado: (2011)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8
por: Soto, Cinque, et al.
Publicado: (2016)

An MPER antibody neutralizes HIV-1 using germline features shared among donors
por: Zhang, Lei, et al.
Publicado: (2019)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies
por: Richardson, Simone I., et al.
Publicado: (2018)

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
por: van Schooten, Jelle, et al.
Publicado: (2022)

Correction: Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
Publicado: (2015)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses
por: Jia, Janice Zhirong, et al.
Publicado: (2022)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
por: Kitchin, D, et al.
Publicado: (2019)

Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2013)

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
por: Motsoeneng, Boitumelo M., et al.
Publicado: (2023)

P19-50. Simulation of an MPER peptide samples epitope conformations of two broadly neutralizing antibodies
por: Wiehe, K, et al.
Publicado: (2009)

Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization
por: Kim, Arthur S., et al.
Publicado: (2014)

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
por: Molinos-Albert, Luis M, et al.
Publicado: (2014)

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies
por: Ruprecht, C, et al.
Publicado: (2009)

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
por: van Schooten, Jelle, et al.
Publicado: (2018)

The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes
por: Bai, Hongjun, et al.
Publicado: (2019)

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth
por: Roskin, Krishna M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3laaqrnguhc29qrgftr60uff2